TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Evidence that cholesterol-lowering drugs prevent or treat Alzheimer’s remains unsettled. A long-term Danish observational study linked statin use with lower dementia risk, while a subgroup analysis of a Phase 3 obicetrapib trial found reduced blood pTau-217 in ApoE4 carriers; neither finding establishes that the drugs prevent or slow Alzheimer’s.
New evidence has renewed questions about whether cholesterol-lowering drugs could affect Alzheimer’s: a Danish study associated statin use with lower dementia risk, and a subgroup analysis of a Phase 3 trial found that obicetrapib lowered a blood Alzheimer’s biomarker in people carrying the ApoE4 risk gene. Neither result shows that the drugs prevent or treat Alzheimer’s, and researchers say further trials measuring cognition are needed.
In a study published in Lancet Regional Health Europe, researchers led by Shoaib Afzal of Copenhagen University Hospital analyzed electronic health records for more than 130,000 people with Type 2 diabetes. The report said people who began statins earlier had a 15% lower dementia risk over a decade, while those who started later had a 10% lower risk. Because this was an observational study, it found an association and cannot establish that statins caused the difference.
A separate finding comes from a study of obicetrapib, a NewAmsterdam Pharma drug in the cholesteryl ester transfer protein (CETP) inhibitor class. Among 1,727 Phase 3 trial participants who carried ApoE4, the drug lowered blood levels of pTau-217, a biomarker used in Alzheimer’s assessment. The trial involved people with heart disease or a genetic form of high cholesterol; the biomarker result does not show that participants’ memory or thinking improved.
NewAmsterdam has enrolled the first participant in a Phase 2b Alzheimer’s trial of obicetrapib. The study is intended to test whether one year of treatment changes Alzheimer’s biomarkers in people who have disease hallmarks but no symptoms. The reported trial aims to examine biomarker changes, not to establish that the drug prevents dementia or treats symptoms.
Why Biomarker Results Matter
The findings matter because they point to two different research questions: whether statins are associated with dementia risk over many years, and whether a newer drug can alter a marker linked to Alzheimer’s biology. A blood biomarker shift may help researchers decide whether a treatment deserves further study, but it is not the same as evidence that people think better, develop symptoms later, or avoid dementia.
For patients, the distinction is practical. Statins are commonly prescribed to reduce cardiovascular risk, including stroke risk for many people with diabetes, but the evidence presented here does not support taking them specifically to prevent Alzheimer’s. Obicetrapib is also being studied, not established as an Alzheimer’s treatment. Decisions about cholesterol medication should be made with a qualified clinician based on an individual’s health and cardiovascular risks.
statin cholesterol lowering medication
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Statins, the Brain and Earlier Trials
Earlier randomized trials of statins did not show that the drugs treated cognitive decline, according to the source report. A randomized trial in healthy adults older than 70 also failed to find a dementia-prevention effect. These results differ from observational findings, which can be affected by differences between people who take medication and those who do not.
David Knopman, a Mayo Clinic neurologist, told Being Patient that statin users may be more medically informed or more likely to follow healthy behaviors, making comparisons difficult. Long-term randomized prevention trials could address that problem, but Knopman said they may be impractical and expensive, particularly because statins are off-patent. The source article also notes that statins do not readily reach the brain, while cholesterol metabolism within the brain is a separate area of research.
“I’m of the opinion that our traditional way of treating cholesterol with statins is probably not going to work.”
— Heather Ferris, clinical endocrinologist and scientist at the University of Virginia, speaking to Being Patient
blood biomarker testing kit for Alzheimer’s
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What the Evidence Cannot Show
The Danish study cannot determine whether statins themselves explain the lower dementia risk. Differences in health care access, education, health behavior or other factors may influence who starts and continues treatment. The reported 15% and 10% figures describe associations in that study over a decade; they do not establish a protective effect for an individual or apply automatically to people without diabetes.
The obicetrapib result is a biomarker finding in a subgroup, not evidence of improved memory, slowed disease progression or fewer Alzheimer’s diagnoses. The source report does not provide enough detail to establish how durable or clinically meaningful the pTau-217 change is. It also remains unclear whether the Phase 2b trial will show biomarker changes that translate into benefits patients can feel.
As an affiliate, we earn on qualifying purchases.
The Next Obicetrapib Trial
The next reported milestone is the ongoing Phase 2b Alzheimer’s trial, which will assess whether a year of obicetrapib treatment changes biomarkers in people with Alzheimer’s hallmarks but no symptoms. Results could clarify whether the Phase 3 subgroup signal is reproducible in a population selected for Alzheimer’s-related features.
Even a positive biomarker result would not, on its own, prove prevention or treatment. Evidence about cognitive function, clinical progression, safety and longer-term outcomes would still be needed. Researchers also face the challenge of producing stronger evidence on statins: observational studies can suggest a relationship, but the randomized trials that could test cause and effect may be difficult to fund and run.
CETP inhibitor drugs for cholesterol
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
Do statins prevent Alzheimer’s?
That has not been established. The Danish study found an association between statin use and lower dementia risk among people with Type 2 diabetes, while randomized studies cited in the report did not establish a prevention benefit.
Does obicetrapib treat Alzheimer’s?
No treatment benefit has been shown in the evidence described. A Phase 3 trial subgroup analysis found lower blood pTau-217 among ApoE4 carriers, but a biomarker change is not proof of improved cognition or slower disease.
What is pTau-217?
pTau-217 is a blood biomarker used in Alzheimer’s assessment. A change in its level may be relevant to research, but it does not by itself show whether a person’s symptoms or future disease risk have changed.
Should someone take a cholesterol drug to lower Alzheimer’s risk?
The findings do not support starting a cholesterol medicine specifically to prevent Alzheimer’s. People should discuss medication decisions with a qualified clinician, who can weigh their cardiovascular risks and other health factors.
Source: rss
Columbus Day / Indigenous Peoples' Day Picks
long weekend sales
As an affiliate, we earn on qualifying purchases.
